{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:57:49Z","timestamp":1791928669042,"version":"4.3.4"},"reference-count":46,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"7","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2018,6,6]]},"DOI":"10.1167\/iovs.18-24431","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T20:14:08Z","timestamp":1532117648000},"page":"2905","source":"Crossref","is-referenced-by-count":34,"title":["Tumor Necrosis Factor Inhibition in the Acute Management of Traumatic Optic Neuropathy"],"prefix":"10.1167","volume":"59","author":[{"given":"Brian C.","family":"Tse","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Dvoriantchikova","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensi","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Gallo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Pappas","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Brambilla","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"},{"name":"Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Tse","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pelaez","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dr. Nasser Al-Rashid Orbital Vision Research Center, Bascom Palmer Eye Institute, Miami, Florida, United States"},{"name":"Department of Biomedical Engineering, University of Miami, Coral Gables, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"i1552-5783-59-7-2905-b01","doi-asserted-by":"crossref","unstructured":"Guy WM, Soparkar CN, Alford EL, Patrinely JR, Sami MS, Parke RB. Traumatic optic neuropathy and second optic nerve injuries. JAMA Ophthalmol. 2014; 132: 567\u2013571.","DOI":"10.1001\/jamaophthalmol.2014.82"},{"key":"i1552-5783-59-7-2905-b02","doi-asserted-by":"crossref","unstructured":"Kumaran AM, Sundar G, Chye LT. Traumatic optic neuropathy: a review. Craniomaxillofac Trauma Reconstr. 2015; 8: 31\u201341.","DOI":"10.1055\/s-0034-1393734"},{"key":"i1552-5783-59-7-2905-b03","doi-asserted-by":"crossref","unstructured":"Carta A, Ferrigno L, Leaci R, Kosmarikou A, Zola E, Gomarasca S. Long-term outcome after conservative treatment of indirect traumatic optic neuropathy. Eur J Ophthalmol. 2006; 16: 847\u2013850.","DOI":"10.1177\/112067210601600610"},{"key":"i1552-5783-59-7-2905-b04","doi-asserted-by":"crossref","unstructured":"Steinsapir KD. Traumatic optic neuropathy. Curr Opin Ophthalmol. 1999; 10: 340\u2013342.","DOI":"10.1097\/00055735-199910000-00011"},{"key":"i1552-5783-59-7-2905-b05","doi-asserted-by":"crossref","unstructured":"Singman EL, Daphalapurkar N, White H, et al. Indirect traumatic optic neuropathy. Mil Med Res. 2016; 3: 2.","DOI":"10.1186\/s40779-016-0069-2"},{"key":"i1552-5783-59-7-2905-b06","unstructured":"Giza CC, Hovda DA. The neurometabolic cascade of concussion. J Athl Train. 2001; 36: 228\u2013235."},{"key":"i1552-5783-59-7-2905-b07","doi-asserted-by":"crossref","unstructured":"Medeiros FA, Moura FC, Vessani RM, Susanna R Jr. Axonal loss after traumatic optic neuropathy documented by optical coherence tomography. Am J Ophthalmol. 2003; 135: 406\u2013408.","DOI":"10.1016\/S0002-9394(02)02049-4"},{"key":"i1552-5783-59-7-2905-b08","doi-asserted-by":"crossref","unstructured":"Chaon BC, Lee MS. Is there treatment for traumatic optic neuropathy? Curr Opin Ophthalmol. 2015; 26: 445\u2013449.","DOI":"10.1097\/ICU.0000000000000198"},{"key":"i1552-5783-59-7-2905-b09","unstructured":"Yan W, Chen Y, Qian Z, et al. Incidence of optic canal fracture in the traumatic optic neuropathy and its effect on the visual outcome. Br J Ophthalmol. 2017; 101: 261\u2013267."},{"key":"i1552-5783-59-7-2905-b10","doi-asserted-by":"crossref","unstructured":"Goldberg RA, Steinsapir KD. Extracranial optic canal decompression: indications and technique. Ophthal Plast Reconstr Surg. 1996; 12: 163\u2013170.","DOI":"10.1097\/00002341-199609000-00002"},{"key":"i1552-5783-59-7-2905-b11","doi-asserted-by":"crossref","unstructured":"Yu B, Ma Y, Tu Y, Wu W. The outcome of endoscopic transethmosphenoid optic canal decompression for indirect traumatic optic neuropathy with no-light-perception. J Ophthalmol. 2016; 2016: 6492858.","DOI":"10.1155\/2016\/6492858"},{"key":"i1552-5783-59-7-2905-b12","doi-asserted-by":"crossref","unstructured":"Kashkouli MB, Yousefi S, Nojomi M, et al. Traumatic optic neuropathy treatment trial (TONTT): open label, phase 3, multicenter, semi-experimental trial. Graefes Arch Clin Exp Ophthalmol. 2017; 256: 209\u2013218.","DOI":"10.1007\/s00417-017-3816-5"},{"key":"i1552-5783-59-7-2905-b13","doi-asserted-by":"crossref","unstructured":"Yu-Wai-Man P, Griffiths PG. Surgery for traumatic optic neuropathy. Cochrane Database Syst Rev. 2013; 6: CD005024.","DOI":"10.1002\/14651858.CD005024.pub3"},{"key":"i1552-5783-59-7-2905-b14","doi-asserted-by":"crossref","unstructured":"Levin LA, Beck RW, Joseph MP, Seiff S, Kraker R. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology. 1999; 106: 1268\u20131277.","DOI":"10.1016\/S0161-6420(99)00707-1"},{"key":"i1552-5783-59-7-2905-b15","doi-asserted-by":"crossref","unstructured":"Carta A, Ferrigno L, Salvo M, Bianchi-Marzoli S, Boschi A, Carta F. Visual prognosis after indirect traumatic optic neuropathy. J Neurol Neurosurg Psychiatry. 2003; 74: 246\u2013248.","DOI":"10.1136\/jnnp.74.2.246"},{"key":"i1552-5783-59-7-2905-b16","doi-asserted-by":"crossref","unstructured":"Chierzi S, Strettoi E, Cenni MC, Maffei L. Optic nerve crush: axonal responses in wild-type and bcl-2 transgenic mice. J Neurosci. 1999; 19: 8367\u20138376.","DOI":"10.1523\/JNEUROSCI.19-19-08367.1999"},{"key":"i1552-5783-59-7-2905-b17","doi-asserted-by":"crossref","unstructured":"Levkovitch-Verbin H. Animal models of optic nerve diseases. Eye (Lond). 2004; 18: 1066\u20131074.","DOI":"10.1038\/sj.eye.6701576"},{"key":"i1552-5783-59-7-2905-b18","doi-asserted-by":"crossref","unstructured":"Xue F, Wu K, Wang T, Cheng Y, Jiang M, Ji J. Morphological and functional changes of the optic nerve following traumatic optic nerve injuries in rabbits. Biomed Rep. 2016; 4: 188\u2013192.","DOI":"10.3892\/br.2016.567"},{"key":"i1552-5783-59-7-2905-b19","doi-asserted-by":"crossref","unstructured":"Tao W, Dvoriantchikova G, Tse BC, et al. A novel mouse model of traumatic optic neuropathy using external ultrasound energy to achieve focal, indirect optic nerve injury. Sci Rep. 2017; 7: 11779.","DOI":"10.1038\/s41598-017-12225-6"},{"key":"i1552-5783-59-7-2905-b20","doi-asserted-by":"crossref","unstructured":"Venters HD, Dantzer R, Kelley KW. A new concept in neurodegeneration: TNFalpha is a silencer of survival signals. Trends Neurosci. 2000; 23: 175\u2013180.","DOI":"10.1016\/S0166-2236(99)01533-7"},{"key":"i1552-5783-59-7-2905-b21","doi-asserted-by":"crossref","unstructured":"Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000; 32: 42\u201350.","DOI":"10.1002\/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3"},{"key":"i1552-5783-59-7-2905-b22","doi-asserted-by":"crossref","unstructured":"Liefner M, Siebert H, Sachse T, Michel U, Kollias G, Bruck W. The role of TNF-alpha during Wallerian degeneration. J Neuroimmunol. 2000; 108: 147\u2013152.","DOI":"10.1016\/S0165-5728(00)00262-9"},{"key":"i1552-5783-59-7-2905-b23","doi-asserted-by":"crossref","unstructured":"Kitaoka Y, Sase K, Tsukahara C, et al. Axonal protection by ripasudil, a rho kinase inhibitor, via modulating autophagy in TNF-induced optic nerve degeneration. Invest Ophthalmol Vis Sci. 2017; 58: 5056\u20135064.","DOI":"10.1167\/iovs.17-22000"},{"key":"i1552-5783-59-7-2905-b24","doi-asserted-by":"crossref","unstructured":"Russell AE, Doll DN, Sarkar SN, Simpkins JW. TNF-alpha and beyond: rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity. J Clin Cell Immunol. 2016; 7: 467\u2013470.","DOI":"10.4172\/2155-9899.1000467"},{"key":"i1552-5783-59-7-2905-b25","doi-asserted-by":"crossref","unstructured":"Viviani B, Corsini E, Galli CL, Marinovich M. Glia increase degeneration of hippocampal neurons through release of tumor necrosis factor-alpha. Toxicol Appl Pharmacol. 1998; 150: 271\u2013276.","DOI":"10.1006\/taap.1998.8406"},{"key":"i1552-5783-59-7-2905-b26","doi-asserted-by":"crossref","unstructured":"Dvoriantchikova G, Ivanov D. Tumor necrosis factor-alpha mediates activation of NF-kappaB and JNK signaling cascades in retinal ganglion cells and astrocytes in opposite ways. Eur J Neurosci. 2014; 40: 3171\u20133178.","DOI":"10.1111\/ejn.12710"},{"key":"i1552-5783-59-7-2905-b27","doi-asserted-by":"crossref","unstructured":"Dvoriantchikova G, Santos AR, Saeed AM, Dvoriantchikova X, Ivanov D. Putative role of protein kinase C in neurotoxic inflammation mediated by extracellular heat shock protein 70 after ischemia-reperfusion. J Neuroinflamm. 2014; 11: 81.","DOI":"10.1186\/1742-2094-11-81"},{"key":"i1552-5783-59-7-2905-b28","doi-asserted-by":"crossref","unstructured":"Tezel G, Yang X, Yang J, Wax MB. Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. Brain Res. 2004; 996: 202\u2013212.","DOI":"10.1016\/j.brainres.2003.10.029"},{"key":"i1552-5783-59-7-2905-b29","doi-asserted-by":"crossref","unstructured":"Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci. 2002; 22: RC216.","DOI":"10.1523\/JNEUROSCI.22-07-j0001.2002"},{"key":"i1552-5783-59-7-2905-b30","doi-asserted-by":"crossref","unstructured":"Topdag M, Iseri M, Topdag DO, Kokturk S, Ozturk M, Iseri P. The effect of etanercept and methylprednisolone on functional recovery of the facial nerve after crush injury. Otol Neurotol. 2014; 35: 1277\u20131283.","DOI":"10.1097\/MAO.0000000000000359"},{"key":"i1552-5783-59-7-2905-b31","doi-asserted-by":"crossref","unstructured":"Dvoriantchikova G, Pappas S, Luo X, et al. Virally delivered, constitutively active NFkappaB improves survival of injured retinal ganglion cells. Eur J Neurosci. 2016; 44: 2935\u20132943.","DOI":"10.1111\/ejn.13383"},{"key":"i1552-5783-59-7-2905-b32","doi-asserted-by":"crossref","unstructured":"Chou TH, Bohorquez J, Toft-Nielsen J, Ozdamar O, Porciatti V. Robust mouse pattern electroretinograms derived simultaneously from each eye using a common snout electrode. Invest Ophthalmol Vis Sci. 2014; 55: 2469\u20132475.","DOI":"10.1167\/iovs.14-13943"},{"key":"i1552-5783-59-7-2905-b33","doi-asserted-by":"crossref","unstructured":"Kalesnykas G, Oglesby EN, Zack DJ, et al. Retinal ganglion cell morphology after optic nerve crush and experimental glaucoma. Invest Ophthalmol Vis Sci. 2012; 53: 3847\u20133857.","DOI":"10.1167\/iovs.12-9712"},{"key":"i1552-5783-59-7-2905-b34","doi-asserted-by":"crossref","unstructured":"Cheong CU, Chang CP, Chao CM, Cheng BC, Yang CZ, Chio CC. Etanercept attenuates traumatic brain injury in rats by reducing brain TNF-alpha contents and by stimulating newly formed neurogenesis. Mediators Inflamm. 2013; 2013: 620837.","DOI":"10.1155\/2013\/620837"},{"key":"i1552-5783-59-7-2905-b35","doi-asserted-by":"crossref","unstructured":"Chio CC, Lin JW, Chang MW, et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010; 115: 921\u2013929.","DOI":"10.1111\/j.1471-4159.2010.06969.x"},{"key":"i1552-5783-59-7-2905-b36","doi-asserted-by":"crossref","unstructured":"Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000; 34: 161\u2013164.","DOI":"10.1345\/aph.19126"},{"key":"i1552-5783-59-7-2905-b37","doi-asserted-by":"crossref","unstructured":"Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014; 28: 679\u2013697.","DOI":"10.1007\/s40263-014-0174-2"},{"key":"i1552-5783-59-7-2905-b38","doi-asserted-by":"crossref","unstructured":"Murdaca G, Spano F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf. 2013; 12: 187\u2013193.","DOI":"10.1517\/14740338.2013.755957"},{"key":"i1552-5783-59-7-2905-b39","doi-asserted-by":"crossref","unstructured":"Tsouni P, Bill O, Truffert A, et al. Anti-TNF alpha medications and neuropathy. J Peripher Nerv Syst. 2015; 20: 397\u2013402.","DOI":"10.1111\/jns.12147"},{"key":"i1552-5783-59-7-2905-b40","doi-asserted-by":"crossref","unstructured":"Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997; 385: 729\u2013733.","DOI":"10.1038\/385729a0"},{"key":"i1552-5783-59-7-2905-b41","doi-asserted-by":"crossref","unstructured":"Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF\/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988; 53: 45\u201353.","DOI":"10.1016\/0092-8674(88)90486-2"},{"key":"i1552-5783-59-7-2905-b42","doi-asserted-by":"crossref","unstructured":"Richter C, Messerschmidt S, Holeiter G, et al. The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand. Mol Cell Biol. 2012; 32: 2515\u20132529.","DOI":"10.1128\/MCB.06458-11"},{"key":"i1552-5783-59-7-2905-b43","doi-asserted-by":"crossref","unstructured":"Brambilla R, Ashbaugh JJ, Magliozzi R, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. J Neurol. 2011; 134: 2736\u20132754.","DOI":"10.1093\/brain\/awr199"},{"key":"i1552-5783-59-7-2905-b44","doi-asserted-by":"crossref","unstructured":"Madsen PM, Clausen BH, Degn M, et al. Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia. J Cereb Blood Flow Metab. 2016; 36: 1553\u20131569.","DOI":"10.1177\/0271678X15610339"},{"key":"i1552-5783-59-7-2905-b45","doi-asserted-by":"crossref","unstructured":"Ye J, Jiang R, Cui M, et al. Etanercept reduces neuroinflammation and lethality in mouse model of Japanese encephalitis. J Infect Dis. 2014; 210: 875\u2013889.","DOI":"10.1093\/infdis\/jiu179"},{"key":"i1552-5783-59-7-2905-b46","doi-asserted-by":"crossref","unstructured":"Bae HW, Lee N, Seong GJ, Rho S, Hong S, Kim CY. Protective effect of etanercept, an inhibitor of tumor necrosis factor-alpha, in a rat model of retinal ischemia. BMC Ophthalmol. 2016; 16: 75.","DOI":"10.1186\/s12886-016-0262-9"}],"container-title":["Investigative Opthalmology &amp; Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?articleid=2683960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:30:54Z","timestamp":1791927054000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.18-24431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.18-24431","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,6]]}}}